by Dr.Joseph Mercola, Mercola.com
According to interim estimates released by the US Centers for Disease Control and Prevention (CDC) on February 15, 2019 — which uses data from 3,254 adults and children enrolled in the US Influenza Vaccine Effectiveness Network between November 23, 2018, and February 2, 2019 — the overall adjusted effectiveness of the 2018-19 flu vaccine against all influenza virus infection associated with acute respiratory illness (ARI) needing medical attention was 47 percent.
While the media has played this up as “good news,” and the CDC calls the results “encouraging,” the fact of the matter is the vaccine failed to offer any protection more than half of the time, and for adults over 50, it’s more or less useless.
Among children aged 6 months to 17 years, the 2018 –19 seasonal flu vaccine had an average effectiveness of 61 percent. However, among adults over 50, which is the most vulnerable group, the vaccine had a mere 24 percent effectiveness against all influenza types, and an abysmal 8 percent against influenza A(H1N1)pdm09 infection, which was by far the most common type.
According to the CDC, the A(H1N1)pdm09 virus was responsible for 74 percent of all influenza A infections for which subtype information was available. What’s more, the CDC notes that, “Among the 3,254 children and adults with ARI … a total of 465 (14 percent) tested positive for influenza virus by real time RT-PCR …”
In other words, of all the people who came down with acute respiratory illness, only 14 percent actually had confirmed influenza. In the vast majority of cases — 86 percent — their respiratory illness was associated with a viral or bacterial infection caused by something other than a type A or B influenza virus.
© 2019 Dr. Joseph Mercola